uploads/2018/02/ALKS-3-1.png

A Look at Alkermes’ Diabetes Product Portfolio

By

Updated

Ampyra and Fampyra

Manufactured by Alkermes (ALKS), Ampyra/Fampyra is regarded as the first approved treatment in the US and more than 50 countries across Europe and Asia. This drug is intended to improve the ability to walk in adults suffering from multiple sclerosis.

The drug is sold in the US by Acorda Therapeutics (ACOR) under the brand name Ampyra and outside the US by Biogen (BIIB) under the brand name Fampyra.

Multiple sclerosis is a chronic, progressive disease in which the immune system attacks and degrades the function of nerve fibers in the brain and spinal cord. These fibers are covered by a myelin sheath, which is damaged by the body’s own immune system. This damage impairs neurological functions in multiple sclerosis patients.

Article continues below advertisement

Bydureon and Bydureon BCise

Bydureon is approved in the US and the European Union for the treatment of type 2 diabetes. Bydureon is developed, manufactured, and marketed by AstraZeneca (AZN) worldwide. The drug is developed using Alkermes’ polymer-based microsphere injectable extended-release technology

AstraZeneca received FDA approval for a new formulation of Bydureon in a single-dose autoinjector device, called Bydureon BCise, for the treatment of patients with type 2 diabetes. AstraZeneca announced the launch of the drug in the US market in January 2018.

Type 2 diabetes

Patients with diabetes don’t produce or efficiently use insulin. Diabetes can lead to health complications including cardiovascular, kidneys and nerve diseases. According to Alkermes, ~26.0 million people in the US and 382.0 million people globally are affected by diabetes. An estimated 90.0%–95.0% of these affected patients have type 2 diabetes. Approximately 80.0% of people with type 2 diabetes are overweight.

In the next part of this series, we’ll look at Alkermes’ drug pipeline.

Advertisement

More From Market Realist